Masaki Tsutomu, Morishita Asahiro, Kurokohchi Kazutaka, Kuriyama Shigeki
Kagawa Medical University, Third Department of Internal Medicine, 1750-1 Ikenobe Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
Expert Rev Anticancer Ther. 2006 Oct;6(10):1377-84. doi: 10.1586/14737140.6.10.1377.
Hepatocellular carcinoma is one of the most common malignancies in the world. When it is diagnosed, patients can choose from among several potentially curative treatments, such as surgical resection, transplantation, ablation therapy and transcatheter arterial chemoembolization. This review will give an overview of the present management of hepatocellular carcinoma. Liver transplantation is considered the best curative option, achieving a high rate of complete response, especially in patients with small hepatocellular carcinoma and good residual liver function. However, a shortage of donor livers restricts the availability of transplantation. In addition, only a minority of patients with hepatocellular carcinoma can be treated surgically, owing to impaired hepatic reserve, multiple intrahepatic lesions, extrahepatic lesions and the inability to obtain an optimal tumor-free margin. Therefore, for most patients, other types of interventions (transcatheter arterial chemoembolization, percutaneous ethanol injection and radiofrequency ablation) have been developed. Among them, two local ablative modalities, percutaneous ethanol injection and percutaneous radiofrequency ablation, have been accepted as the only potentially curative nonsurgical treatments for hepatocellular carcinoma. Radiofrequency ablation may become a standard nonsurgical treatment option for patients with early hepatocellular carcinoma.
肝细胞癌是全球最常见的恶性肿瘤之一。确诊后,患者可以从几种可能治愈的治疗方法中进行选择,如手术切除、移植、消融治疗和经动脉化疗栓塞。本综述将概述肝细胞癌目前的治疗方法。肝移植被认为是最佳的治愈选择,完全缓解率很高,尤其是对于小肝细胞癌且残余肝功能良好的患者。然而,供体肝脏短缺限制了移植的可及性。此外,由于肝储备功能受损、肝内多发病变、肝外病变以及无法获得最佳的无瘤切缘,只有少数肝细胞癌患者能够接受手术治疗。因此,对于大多数患者,已开发出其他类型的干预措施(经动脉化疗栓塞、经皮乙醇注射和射频消融)。其中,两种局部消融方式,即经皮乙醇注射和经皮射频消融,已被公认为肝细胞癌唯一潜在治愈性的非手术治疗方法。射频消融可能成为早期肝细胞癌患者的标准非手术治疗选择。